Sunday, 20 September 2026European Markets

FAGRON Stock Impressive Jump 16% On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - Shares of FAGRON (BEL 20: FAGR.BR) rose by a staggering 16.09% to 15.15 € at 16:12 EST on Thursday, following the last session's downward trend. BEL 20 is rising 0.59% to 3,924.69 €, following the last session's upward trend. This seems, so far, a somewhat up trend trading session today.

About FAGRON

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Earnings Per Share

As for profitability, FAGRON has a trailing twelve months EPS of 0.82 €.

PE Ratio

FAGRON has a trailing twelve months price to earnings ratio of 18.48. Meaning, the purchaser of the share is investing 18.48 € for every euro of annual earnings.

Volatility

FAGRON's last week, last month's, and last quarter's current intraday variation average was a negative 0.31%, a negative 0.37%, and a positive 1.03%.

FAGRON's highest amplitude of average volatility was 0.66% (last week), 0.90% (last month), and 1.03% (last quarter).

More news about FAGRON (FAGR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com